PFE · Earnings call · 2026Q3T · Full report

Oncology Pipeline Progress

PFIZER INC · 2026-11-03 · Importance 30 · Surprise 24

Pfizer is expanding development of tivonatinib, a PD-1/VEGF bispecific, with more than 1,200 patients treated globally and two Phase 3 trials underway; two additional Phase 3 trials were expected to begin that year. In an ongoing Phase 2 study in first-line non-small cell lung cancer, management reported response rates of approximately 80% and median progression-free survival of nearly 14 months for both nonsquamous and squamous histologies. Pfizer said the results strengthened its confidence while acknowledging the limitations of cross-trial comparisons.

Key facts

• Pfizer estimates Elrexfio's eligible patient population could grow approximately fivefold, pending clinical and regulatory success in additional pivotal studies.
• Pfizer started a Phase 1 study of an internally discovered PIK3CA inhibitor.
• Pfizer started the bladder-sparing Padcev-pembrolizumab study 309 and planned a Phase 3 trial of Padcev plus gedatolisib for later in 2026.
• Pfizer expects to initiate a Phase 3 early breast cancer trial combining atermaciclib and giredestrant within the next few months.
• Pfizer has two ongoing Phase 3 tivonatinib trials and expects two additional Phase 3 trials to begin in 2026.
• The Seagen acquisition doubled the size of Pfizer's early-stage oncology pipeline at the time it closed.
• Pfizer's Elrexfio has delivered two positive Phase 3 readouts in double-class-exposed multiple myeloma.
• In MM32, Elrexfio monotherapy significantly improved progression-free survival versus investigator's choice of three standard-of-care regimens in double-class-exposed multiple myeloma.